Literature DB >> 25821741

Solitary painful ulcerated plaque on the sole.

Shahid Hassan1, Anupam Das2, Piyush Kumar1.   

Abstract

Entities:  

Year:  2015        PMID: 25821741      PMCID: PMC4375762          DOI: 10.4103/2229-5178.153022

Source DB:  PubMed          Journal:  Indian Dermatol Online J        ISSN: 2229-5178


× No keyword cloud information.
Sir, A 40-year-old lady presented with a painful ulcerated plaque over the sole of the right foot since four months [Figure 1]. She gave a history of thorn prick prior to onset of symptoms, followed by discoloration and ulceration. Multiple courses of antibiotic were prescribed without relief. Cutaneous examination revealed a single well-defined plaque of 3 cm × 6 cm on the right sole. The surface of the plaque was ulcerated and crusted, with blackish hyperpigmentation and erythema. Mucocutaneous examination, and examination of the draining lymph nodes were unremarkable. Acral lentiginous melanoma, Bowen's disease, lupus vulgaris, and atypical mycobacterial infection were considered in the clinical differentials. Punch biopsy was done from the margin of the lesion. Histological examination showed hyperkeratosis without parakeratosis, focal hypergranulosis, irregular acanthosis, mononuclear cell infiltration in upper dermis, and foci of basal layer degeneration [Figure 2a–c]. Additionally, there were some changes consistent with reactive eccrine syringofibroadematosis. Routine laboratory tests including serum biochemistry panel were absolutely normal. Based on the clinical and histological findings, a diagnosis of ulcerative lichen planus (LP) of the sole was made. She was given intralesional triamcinolone at monthly interval and potent topical steroids under occlusion. There was a satisfactory response, but the lesions did not resolve completely at the end of 2 months. Oral prednisolone was then started at a dose of 1 mg/kg/day, resulting in rapid resolution of the lesion. She has been under regular follow up, and no recurrence has been noted.
Figure 1

Single ulcerated plaque on sole

Figure 2

(a) Hyperkeratosis without parakeratosis, acanthosis, hypergranulosis, and mononuclear cell infiltration in upper dermis (a; H and E, ×40). Note basal layer degeneration (b; H and E, ×400) and (c; H and E, ×400)

Single ulcerated plaque on sole (a) Hyperkeratosis without parakeratosis, acanthosis, hypergranulosis, and mononuclear cell infiltration in upper dermis (a; H and E, ×40). Note basal layer degeneration (b; H and E, ×400) and (c; H and E, ×400) Ulcerative or erosive LP is a rare variant of LP that predominantly affects the oral cavity and genitalia. Plantar location is uncommon and only few cases have been reported in medical literature. It was first described by Friedman in 1921.[1] It is difficult to diagnose ulcerative LP of the sole, especially when it appears as an isolated finding as seen in our case. It usually starts as erythema and bullae on the feet, eventually progressing to develop painful ulcers. Patients have chronic, progressive, crippling, erosive and ulcerative lesions resulting in scarring and deformities.[2] Atypical locations have been reported in a few cases, such as the pretibial zone and flexural areas.[3] Many authors have proposed the association of ulcerative LP and autoimmune diseases, mainly autoimmune thyroiditis, primary biliary cirrhosis, diabetes mellitus, rheumatoid arthritis, and Sjögren's syndrome.[4] The clinical differentials include severe eczema, localized bullous pemphigoid on the soles, and plantar erythrodysesthesia caused by anticancer drugs like gefitinib. Since the condition is rare, a well-accepted therapeutic modality is yet to be discovered.[5] Many modalities are reported to provide symptomatic relief without any long term cure rates, leading to recurrences. A few authors have found systemic steroids beneficial in the long term management of ulcerative LP.[6] There are reports of successful use of intralesional triamcinolone acetonide, low molecular weight heparin,[7] platelet-derived growth factor,[1] and topical tacrolimus. Close follow-up is required as verrucous carcinoma is known to develop in long-standing cases of ulcerative LP; however, the exact incidence of malignancy is not yet known. Our case had additional features of reactive eccrine syringofibroadematosis on histopathology; the latter is a known association of ulcerative LP.[8]
  8 in total

1.  Ulcerative lichen planus: a case responding to recombinant platelet-derived growth factor BB and immunosuppression.

Authors:  U Wollina; H Konrad; T Graefe
Journal:  Acta Derm Venereol       Date:  2001 Oct-Nov       Impact factor: 4.437

2.  Erosive lichen planus on an atypical site mimicking a factitial dermatitis.

Authors:  Carmelo Schepis; Maria Lentini; Maddalena Siragusa
Journal:  Acta Derm Venereol       Date:  2010-03       Impact factor: 4.437

3.  Ulcerative lichen planus of the foot.

Authors:  A Chopra; C Jain; R K Bahl
Journal:  Indian J Dermatol Venereol Leprol       Date:  1996 Jan-Feb       Impact factor: 2.545

4.  Ulcerative lichen planus associated with Sjögren's syndrome.

Authors:  Hiromi Tsuboi; Kensei Katsuoka
Journal:  J Dermatol       Date:  2007-02       Impact factor: 4.005

5.  Effective treatment of erosive lichen planus with thalidomide and topical tacrolimus.

Authors:  Haritini Petropoulou; George Kontochristopoulos; Olga Kalogirou; Irine Panteri; Nikoleta Zakopoulou
Journal:  Int J Dermatol       Date:  2006-10       Impact factor: 2.736

6.  Treatment of severe cutaneous ulcerative lichen planus with low molecular weight heparin in a patient with hepatitis C.

Authors:  Julie A Neville; John G Hancox; Phillip M Williford; Gil Yosipovitch
Journal:  Cutis       Date:  2007-01

7.  Eccrine syringofibroadenoma in a patient with erosive palmoplantar lichen planus.

Authors:  L E French; E Masgrau; P Chavaz; J H Saurat
Journal:  Dermatology       Date:  1997       Impact factor: 5.366

8.  Erosive lichen planus of the soles: Effective response to prednisone.

Authors:  Samia Goucha; Aida Khaled; Zaineb Bennani; Soumeya Rammeh; Faten Zéglaoui; Rachida Zermani; Bécima Fazaa
Journal:  Dermatol Ther (Heidelb)       Date:  2011-08-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.